JavaScript is disabled for your browser. Some features of this site may not work without it.
Nivolumab in Combination with Ipilimumab versus Nivolumab Monotherapy as First Line Treatment for Advanced Malignant Melanoma: A Cost-Utility Analysis from a Norwegian Healthcare Perspective